Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update

Iqbal J., 2014, Bioresorbable scaffolds: rationale, current status, challenges, and future., Eur Heart J., 35, 765, 10.1093/eurheartj/eht542

Abizaid A., 2014, The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled., EuroIntervention., 10, 1396, 10.4244/EIJV10I12A243

Serruys PW., 2015, A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial., Lancet., 385, 43, 10.1016/S0140-6736(14)61455-0

Kocka V., 2014, Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘Prague 19’., Eur Heart J., 35, 787, 10.1093/eurheartj/eht545

Brugaletta S., 2015, Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction)., JACC Cardiovasc Interv., 8, 189, 10.1016/j.jcin.2014.10.005

Diletti R., 2014, Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study., Eur Heart J., 35, 777, 10.1093/eurheartj/eht546

Raber L., 2014, Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: an optical coherence tomography study., Int J Cardiol., 173, 259, 10.1016/j.ijcard.2014.02.036

Serruys PW., 2014, Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months., EuroIntervention., 9, 1271, 10.4244/EIJV9I11A217

Serruys PW., 2016, A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up., J Am Coll Cardiol., 67, 766, 10.1016/j.jacc.2015.11.060

Onuma Y., 2013, Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial., JACC Cardiovasc Interv., 6, 999, 10.1016/j.jcin.2013.05.017

Widimsky P., 2015, One-Year Clinical and Computed Tomography Angiographic Outcomes After Bioresorbable Vascular Scaffold Implantation During Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: The PRAGUE-19 Study., Circ Cardiovasc Interv., 8, e002933, 10.1161/CIRCINTERVENTIONS.115.002933

Cutlip DE., 2007, Clinical end points in coronary stent trials: a case for standardized definitions., Circulation., 115, 2344, 10.1161/CIRCULATIONAHA.106.685313

Okamura T., 2010, Reproducibility of coronary Fourier domain optical coherence tomography: quantitative analysis of in vivo stented coronary arteries using three different software packages., EuroIntervention., 6, 371, 10.4244/EIJV6I1A62

Garcia-Garcia HM., 2014, Assessing bioresorbable coronary devices: methods and parameters., JACC Cardiovasc Imaging., 7, 1130, 10.1016/j.jcmg.2014.06.018

Otsuka F., 2014, Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model., Circ Cardiovasc Interv., 7, 330, 10.1161/CIRCINTERVENTIONS.113.000990

Lu C., 2016, The Safety and Efficacy of Absorb Bioresorbable Vascular Scaffold: A Systematic Review., Clin Cardiol., 39, 48, 10.1002/clc.22451

Tousek P., 2016, Two-year follow-up after bioresorbable vascular scaffold implantation in STEMI patients - Results from PRAGUE-19 study., Int J Cardiol., 209, 20, 10.1016/j.ijcard.2016.02.029

Sabaté M., 2016, Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial., Eur Heart J., 37, 229, 10.1093/eurheartj/ehv500

Cassese S., 2016, Bioresorbable Vascular Scaffold Technology Benefits From Healthy Skepticism., J Am Coll Cardiol., 67, 932, 10.1016/j.jacc.2015.12.020

Lipinski MJ., 2016, Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis., JACC Cardiovasc Interv., 9, 12, 10.1016/j.jcin.2015.09.024

Rumiz Gonzalez E., 2016, Very Late Thrombosis of a Bioresorbable Scaffold., Rev Esp Cardiol (Engl. Ed)., 69, 211, 10.1016/j.recesp.2015.05.016

Räber L., 2015, Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings., J Am Coll Cardiol., 66, 1901, 10.1016/j.jacc.2015.08.853

Timmers L., 2015, Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy., Eur Heart J., 36, 393, 10.1093/eurheartj/ehu419

Yahagi K., 2015 Oct 31, Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy., Cardiovasc Interv Ther., Epub AOP

Ielasi A., 2015, Late Structural Discontinuity as a Possible Cause of Very Late Everolimus-Eluting Bioresorbable Scaffold Thrombosis., JACC Cardiovasc Interv., 8, e171, 10.1016/j.jcin.2015.03.035

Onuma Y., 2014, Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)., JACC Cardiovasc Interv., 7, 1400, 10.1016/j.jcin.2014.06.016